Annual Report 2024

Founded in 1990, the Group is mainly engaged in the research and development, production and sales of pharmaceuticals, and ranks among the leading integrated pharmaceutical companies in China. The Group witnessed its listing on the Main Board of the Hong Kong Stock Exchange on 15 June 2007 (Stock Code: 3933). At present, the Group stands as a constituent stock of the Hang Seng Composite Index series, and maintains MSCI ESG rating at A, which is an industry leading rating. Over three decades of rapid development, the Group has extended its product mix from antibiotics since its establishment to the fields of biopharmaceuticals and animal healthcare, and continues to optimize its vertically integrated business model. The Group currently owns seven production bases, covering intermediate products and bulk medicine, finished products, veterinary drugs, empty capsule casings, and medical devices, with sales networks dotted across nearly 80 countries and regions worldwide. The Group continue to expand its fields of drug research and development and foster a greater global outlook. To make it happen, the Group seeks footprints in multi-platforms for collaborative development focusing on endocrine, metabolism, autoimmunity, anti-infection, ophthalmology and other fields, and several class 1 new drugs have entered the clinical trial stage. The Group presently has over 100 projects under research and development and has attained over 120 patents. Keeping the corporate mission of “Making Life More Valuable” in mind, the Group will, closely following the national development strategy, continue to promote research and development innovation and industrial upgrading, provide the market with more quality and efficient products and services, and accelerate the high-quality development of China and the global pharmaceutical industry.